ReviewInflammopharmacology2025
The forgotten inflammasomes: AIM2, NLRP1, and NLRC4 in spinal cord injury and neuroinflammation.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of Pattern Recognition Receptors (PRRs) in Spinal Cord Injury (SCI): A Comprehensive Review.Molecular neurobiology · 2026Review
- From anthelmintic to neurotherapeutic: exploring the regenerative potential of niclosamide in sciatic nerve injury.Inflammopharmacology · 2026Article
- Glaucocalyxin A Promotes Spinal Cord Repair By Nrf2/HO-1 Pathway Activation to Suppress AIM2 Inflammasome Formation.Molecular neurobiology · 2026Article
- The forgotten inflammasomes: AIM2, NLRP1, and NLRC4 in spinal cord injury and neuroinflammation.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) triggers a cascade of secondary events, among which neuroinflammation plays a central role in driving tissue damage and functional deficits. Inflammasomes are multiprotein complexes that sense cellular stress and mediate caspase-1 activation, interleukin (IL)-1β and IL-18 maturation, and pyroptotic cell death. While the NLRP3 inflammasome has been extensively studied in SCI, emerging evidence suggests that other inflammasomes, including NLRP1, AIM2, and NLRC4, may also contribute to the neuroinflammatory process. This review summarizes current knowledge on non-NLRP3 inflammasomes in SCI, highlighting their distinct activators, cellular distributions, and possible roles in secondary injury. NLRP1 has been implicated in neuronal pyroptosis and axonal degeneration, AIM2 may link mitochondrial and nuclear DNA damage to microglial activation, and NLRC4 has been associated with macrophage- and microglia-driven inflammatory responses. Although evidence remains limited compared to NLRP3, these inflammasomes represent potential contributors to SCI pathology and may serve as novel therapeutic targets. Further experimental and translational studies are needed to clarify their roles and to evaluate pharmacological strategies aimed at modulating their activity.
Indexed as
Identifiers
41105347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.